Abstract:Aging and replicative cellular senescence are associated with the reduced therapeutic potential of mesenchymal stem cells (MSCs) on a variety of diseases. This study aimed to determine the mechanism in MSC senescence and further explore a modification strategy to reverse senescence-associated cell dysfunction to improve the therapeutic efficacy of MSCs on acute liver failure (ALF). We found that the adipose tissue-derived MSCs from old mice (oAMSCs) exhibited senescence phenotypes and showed reduced therapeutic efficacy in lipopolysaccharide and D-galactosamine-induced ALF, as shown by the increased hepatic necrosis, liver histology activity index scores, serum liver function indicator levels, and inflammatory cytokine levels. The expression of miR-17-92 cluster members, especially miR-17 and miR-20a, was obviously decreased in oAMSCs and replicatively senescent AMSCs, and was consistent with the decreased oncogene c-Myc level during AMSC senescence and may mediate c-Myc stemness addiction. Further experiments revealed that c-Myc-regulated miR-17-92 expression contributed to increased p21 expression and redox system dysregulation during AMSC senescence. Furthermore, modification of AMSCs with the two key miRNAs in the miR-17-92 cluster mentioned above reversed the senescence features of oAMSCs and restored the therapeutic effect of senescent AMSCs on ALF. In conclusion, the cellular miR-17-92 cluster level is correlated with AMSC senescence and can be used both as an index for evaluating and as a modification target for improving the therapeutic potential of AMSCs. NEW & NOTEWORTHY We reported for the first time that c-Myc-regulated miR-17-92 contributed to increased p21 expression and redox system dysregulation during AMSC senescence and was associated with the reduced therapeutic effects of senescent AMSCs on ALF. Moreover, modifying the expression of the miR-17-92 cluster members, especially miR-17 and/or miR-20a, could reverse AMSC senescence. Thus, miR-17-92 cluster can be used both as an index for evaluating and as a modification strategy for improving the therapeutic potential of AMSCs.

The Mir‐302/367 Cluster: Aging, Inflammation, and Cancer

Molecular Mechanisms and Clinical Applications of Mir-22 in Regulating Malignant Progression in Human Cancer (Review)

Role of miR-302/367 cluster in human physiology and pathophysiology

Elucidation of how the Mir-23-27-24 cluster regulates development and aging

Mir-302 Cluster Inhibits Angiogenesis and Growth of K562 Leukemia Cells by Targeting VEGFA.

Dysregulation and Functional Roles of Mir-183-96-182 Cluster in Cancer Cell Proliferation, Invasion and Metastasis

Expression, regulation and mechanism of action of the miR-17-92 cluster in tumor cells (Review)

Research Progress of microRNA-761

Role of Mir-17-92 Gene Cluster in Tumor Development and Progression

Feud or Friend? the Role of the Mir-17-92 Cluster in Tumorigenesis

Clustered miRNAs and their role in biological functions and diseases

Mirna-214: Expression, Therapeutic and Diagnostic Potential in Cancer

Interactive functions of microRNAs in the miR‐23a‐27a‐24‐2 cluster and the potential for targeted therapy in cancer

Decreased Mir-17-92 Cluster Correlates with Senescence Features, Disrupted Oxidative Homeostasis, and Impaired Therapeutic Efficacy of Mesenchymal Stem Cells

The miR-183 Cluster: Biogenesis, Functions, and Cell Communication via Exosomes in Cancer

Novel Functions of MicroRNA-17-92 Cluster in the Endocrine System

The miR‐15a/16 gene cluster in human cancer: A systematic review

The Mir-17-92 Cluster Of Micrornas Confers Tumorigenicity By Inhibiting Oncogene-Induced Senescence

The microRNA-424/503 cluster: A master regulator of tumorigenesis and tumor progression with paradoxical roles in cancer

Aberrant Expression of microRNA Clusters in Head and Neck Cancer Development and Progression: Current and Future Translational Impacts

miRNA-based biomarkers, therapies, and resistance in Cancer